Specialty Pharmacy: Stakeholders, Strategies and Markets 2011

Specialty Pharmacy: Stakeholders, Strategies and Markets 2011 is a unique resource from Atlantic Information Services, Inc. that includes reliable and concise coverage of today s hottest specialty pharma topics:
* The regulatory pathway for follow-on biologics including estimates of the enormous savings potential, legal controversies and product development
* Developments in personalized medicine including the impact of genetic testing on therapies, comparative effectiveness research, KRAS, and coverage and cost concerns
* Access and supply issues such as the Cerezyme supply shortage, patent issues and FDA approvals and expanded indications
* Health plan payer strategies for specific disease management states, including:
- Oncology
- Human Growth Hormone
- Multiple Sclerosis
- Hemophilia
- Rheumatoid Arthritis
- And more
* Major players in the specialty pharmacy arena including a look at mergers and acquisitions, provider / payer partnerships, joint ventures, contracts and agreements, as well as the job market and the economic outlook for specialty pharmacy

Plus, Specialty Pharmacy: Stakeholders, Strategies and Markets 2011 contains a comprehensive directory of specialty pharmacy and specialty infusion providers, with extensive company descriptions, key personnel contacts and trends.

Table of Contents
Chapter 1: Evolution of the Specialty Pharmacy Market
* Defining the Specialty Pharmacy Industry
* Recent Specialty Pharmacy Mergers and Acquisitions
* Economic Impact and Outlook for Specialty Pharmacy
* Specialty Pharmacy Job Market and Leadership Changes
* Specialty Pharmacy Evolutionary Timeline
Chapter 2: FDA Actions, Approvals and Expanded Indications
Chapter 3: Directory of Specialty Pharmacy and Specialty Infusion Providers and Related Services
Chapter 4: Contracting, Alliances and Partnerships
* Specialty Pharmacy Contracts and Agreements
* Partnerships, Alliances and Joint Ventures
Chapter 5: Strategies for Managing Therapies and Designing Benefits
* Benefit Design and Structure
* Managing Therapies
* Orphan Drugs
* New Products and Services
* Wellness
* REMS and Other Patient Safety Issues
Chapter 6: Payer Strategies for Managing Specific Disease States
* Hemophilia
* Hepatitis
* HIV/AIDS
* Human Growth Hormone
* Kidney Disease
* Multiple Sclerosis
* Ophthalmology
* Rheumatoid Arthritis
* Selected Major Conditions Targeted by Specialty Pharmacy Drugs
Chapter 7: Health Plan Strategies for Oncology Management
* Oral Oncology
* Cost and Reimbursement Issues
* Coverage Challenges
* Clinical Outcomes and Therapies
* Provider/Payer Partnerships
Chapter 8: Access and Supply Issues and Legal Battles
* Cerezyme Supply Shortage
* Coverage Policies
* Patent Issues
Chapter 9: Follow-On Biologics
* Establishing a Regulatory Pathway for Follow-On Biologics
* Product Development
* Savings Potential
* Controversies and Legal Battles
Chapter 10: Cost Trends and Strategies
* Specialty Pharmacy Drug Cost Trends
* Specialty Drug Spend
Chapter 11: Medicare Payment Methodologies and Reimbursement Strategies
* Medicare Part B Issues
* Reimbursement Challenges
* Coding for Avastin
* Medicare Competitive Acquisition Program (CAP)
Chapter 12: Personalized Medicine Developments and Oversight
* Legislation and Regulation of Genetic Testing
* Coverage and Cost Concerns
* Products and Services
* Impact of Genetic Testing on Therapies
* Comparative Effectiveness Research
* KRAS Testing
* Diagnostics